Revenue: As of FY2025, the actual value is USD 14.08 M.

EPS: As of FY2025, the actual value is USD -0.17, beating the estimate of USD -0.1924.

EBIT: As of FY2025, the actual value is USD -42.13 M.

Cash and Investments

Arbutus Biopharma Corporation reported cash, cash equivalents, and marketable securities of $91.5 million as of December 31, 2025, a decrease from $122.6 million as of December 31, 2024. Total cash, cash equivalents, and investments were $91,471 thousand for 2025, compared to $122,623 thousand for 2024.

Cash Flow

Net cash used in operating activities was - $39,637 thousand in 2025, compared to - $64,850 thousand in 2024. The company used - $39.6 million in operating activities during 2025, which included one-time payments related to restructuring efforts, partially offset by $5.5 million from stock option exercises. Net cash provided by investing activities was $15,580 thousand in 2025. Net cash provided by financing activities was $5,721 thousand in 2025.

Revenue

Total revenue for Arbutus Biopharma Corporation was $14.1 million for the year ended December 31, 2025, an increase of $7.9 million from $6.2 million in 2024. Collaborations and licenses revenue was $12,601 thousand in 2025, up from $3,919 thousand in 2024. Non-cash royalty revenue was $1,482 thousand in 2025, down from $2,252 thousand in 2024.

Operating Expenses

Research and development expenses decreased by $28.8 million to $25.2 million in 2025 from $54.0 million in 2024. General and administrative expenses decreased to $15.9 million in 2025 from $22.1 million in 2024. Restructuring costs for 2025 were $12.9 million, compared to $3.7 million in 2024. Total operating expenses were $52,243 thousand in 2025, a decrease from $82,490 thousand in 2024.

Net Loss

Arbutus Biopharma Corporation reported a net loss of - $33.5 million, or - $0.17 per basic and diluted common share, for the year ended December 31, 2025. This compares to a net loss of - $69.9 million, or - $0.38 per basic and diluted common share, for the same period in 2024. Loss from operations was - $38,160 thousand in 2025, compared to - $76,319 thousand in 2024.

Other Key Metrics

As of December 31, 2025, Arbutus Biopharma Corporation had 192.5 million common shares issued and outstanding, along with 14.0 million stock options and unvested restricted stock units outstanding. The company recognized $0.5 million in revenue in December 2025 following a contractual milestone from Alnylam related to LNP technology use in a product candidate for hepatocellular carcinoma.

Outlook / Guidance

Arbutus Biopharma Corporation, along with Genevant, entered into a settlement agreement with Moderna for $950 million upfront in July 2026, with an additional $1.3 billion contingent upon an appellate ruling. Arbutus is entitled to receive 20% of the noncontingent settlement payment after deducting litigation costs. The company is evaluating a return of capital to its shareholders in the third quarter of 2026, following the receipt of its portion of the noncontingent lump sum payment from Moderna.